386 related articles for article (PubMed ID: 16284097)
21. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome.
Tobón GJ; Saraux A; Gottenberg JE; Quartuccio L; Fabris M; Seror R; Devauchelle-Pensec V; Morel J; Rist S; Mariette X; De Vita S; Youinou P; Pers JO
Arthritis Rheum; 2013 Dec; 65(12):3218-27. PubMed ID: 23982978
[TBL] [Abstract][Full Text] [Related]
22. Predictors for the development of non-Hodgkin lymphoma in primary Sjögren's syndrome.
Jonsson MV; Theander E; Jonsson R
Presse Med; 2012 Sep; 41(9 Pt 2):e511-6. PubMed ID: 22867948
[TBL] [Abstract][Full Text] [Related]
23. Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome.
Nocturne G; Virone A; Ng WF; Le Guern V; Hachulla E; Cornec D; Daien C; Vittecoq O; Bienvenu B; Marcelli C; Wendling D; Amoura Z; Dhote R; Lavigne C; Fior R; Gottenberg JE; Seror R; Mariette X
Arthritis Rheumatol; 2016 Apr; 68(4):977-85. PubMed ID: 26606524
[TBL] [Abstract][Full Text] [Related]
24. Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan.
Weng MY; Huang YT; Liu MF; Lu TH
Ann Rheum Dis; 2012 Apr; 71(4):524-7. PubMed ID: 22072014
[TBL] [Abstract][Full Text] [Related]
25. A clinical prediction rule for lymphoma development in primary Sjögren's syndrome.
Baldini C; Pepe P; Luciano N; Ferro F; Talarico R; Grossi S; Tavoni A; Bombardieri S
J Rheumatol; 2012 Apr; 39(4):804-8. PubMed ID: 22337248
[TBL] [Abstract][Full Text] [Related]
26. Increased incidence of Sjogren's syndrome in systemic sclerosis: A nationwide population study.
Tseng CC; Yen JH; Tsai WC; Ou TT; Wu CC; Sung WY; Hsieh MC; Chang SJ
Autoimmunity; 2015; 48(7):438-44. PubMed ID: 25980318
[TBL] [Abstract][Full Text] [Related]
27. Primary Sjögren's syndrome and B-non-Hodgkin lymphoma: role of CD4+ T lymphocytopenia.
Ismail F; Mahmoud A; Abdelhaleem H; Mamdoh A; Geneidy M; Kamal E
Rheumatol Int; 2013 Apr; 33(4):1021-5. PubMed ID: 22886469
[TBL] [Abstract][Full Text] [Related]
28. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome.
Skopouli FN; Dafni U; Ioannidis JP; Moutsopoulos HM
Semin Arthritis Rheum; 2000 Apr; 29(5):296-304. PubMed ID: 10805354
[TBL] [Abstract][Full Text] [Related]
29. Hematologic malignancies in patients with cryoglobulinemia: association with autoimmune and chronic viral diseases.
Trejo O; Ramos-Casals M; López-Guillermo A; García-Carrasco M; Yagüe J; Cervera R; Font J; Ingelmo M
Semin Arthritis Rheum; 2003 Aug; 33(1):19-28. PubMed ID: 12920693
[TBL] [Abstract][Full Text] [Related]
30. Predictable biomarkers of developing lymphoma in patients with Sjögren syndrome: a nationwide population-based cohort study.
Chiu YH; Chung CH; Lin KT; Lin CS; Chen JH; Chen HC; Huang RY; Wu CT; Liu FC; Chien WC
Oncotarget; 2017 Jul; 8(30):50098-50108. PubMed ID: 28177920
[TBL] [Abstract][Full Text] [Related]
31. [Lymphoproliferative disorders in Sjögren's syndrome].
Prochorec-Sobieszek M; Wagner T
Otolaryngol Pol; 2005; 59(4):559-64. PubMed ID: 16273862
[TBL] [Abstract][Full Text] [Related]
32. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses.
Royer B; Cazals-Hatem D; Sibilia J; Agbalika F; Cayuela JM; Soussi T; Maloisel F; Clauvel JP; Brouet JC; Mariette X
Blood; 1997 Jul; 90(2):766-75. PubMed ID: 9226177
[TBL] [Abstract][Full Text] [Related]
33. Sjögren's syndrome in patients with newly diagnosed untreated non-Hodgkin's lymphoma.
Andonopoulos AP; Tiniakou M; Melachrinou M; Sfountouris H; Bounas A; Zervas C; Zoumbos NC
Rev Rhum Engl Ed; 1997 May; 64(5):287-92. PubMed ID: 9190001
[TBL] [Abstract][Full Text] [Related]
34. Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome.
Mofors J; Holmqvist M; Westermark L; Björk A; Kvarnström M; Forsblad-d'Elia H; Magnusson Bucher S; Eriksson P; Theander E; Mandl T; Wahren-Herlenius M; Nordmark G
J Intern Med; 2019 Oct; 286(4):458-468. PubMed ID: 31127862
[TBL] [Abstract][Full Text] [Related]
35. Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren's Syndrome.
Chatzis L; Goules AV; Stergiou IE; Voulgarelis M; Tzioufas AG; Kapsogeorgou EK
Front Immunol; 2021; 12():705079. PubMed ID: 34484201
[TBL] [Abstract][Full Text] [Related]
36. Risk of non-Hodgkin's lymphoma in primary Sjögren's syndrome: a population-based study.
Johnsen SJ; Brun JG; Gøransson LG; Småstuen MC; Johannesen TB; Haldorsen K; Harboe E; Jonsson R; Meyer PA; Omdal R
Arthritis Care Res (Hoboken); 2013 May; 65(5):816-21. PubMed ID: 23139233
[TBL] [Abstract][Full Text] [Related]
37. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
[TBL] [Abstract][Full Text] [Related]
38. [Sjögren's syndrome associated with non-Hodgkin's lymphoma].
Nagai K
Nihon Rinsho; 1995 Oct; 53(10):2574-9. PubMed ID: 8531376
[TBL] [Abstract][Full Text] [Related]
39. Clinical picture, outcome and predictive factors of lymphoma in primary Sjögren's syndrome: results from a harmonized dataset (1981-2021).
Chatzis LG; Stergiou IE; Goules AV; Pezoulas V; Tsourouflis G; Fotiadis D; Tzioufas AG; Voulgarelis M
Rheumatology (Oxford); 2022 Aug; 61(9):3576-3585. PubMed ID: 34940812
[TBL] [Abstract][Full Text] [Related]
40. Incidence of cancer in a cohort of patients with primary Sjogren's syndrome.
Lazarus MN; Robinson D; Mak V; Møller H; Isenberg DA
Rheumatology (Oxford); 2006 Aug; 45(8):1012-5. PubMed ID: 16490754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
